Dr Sjoerd Rijpkema

Peer reviewed publications and WHO reports 2004-2014

2014

Whiting G, Wheeler JX, Rijpkema S. Identification of peptide sequences as a measure of Anthrax vaccine stability during storage. Human Vaccines & Immunotherapeutics 10:6, 1669–1681; http://dx.doi.org/10.4161/hv.28443

2013

Guidelines on the quality, safety and efficacy of typhoid conjugate vaccines. WHO/BS/2215

2012

Whiting G, Baker M, Rijpkema S. Development of an *in vitro* potency assay for anti-anthrax Lethal Toxin neutralizing antibodies. Toxins 4(1), 28-41; doi:10.3390/toxins4010028

2011

Otani M, Hockley J, Guzmán Bracho C, Rijpkema S, Luquetti AO, Duncan R, Rigsby P, Albajar-Viñas P, Padilla A. Evaluation of two International Reference Standards for antibodies to *Trypanosoma cruzi* in a WHO collaborative study. WHO/BS/2011.2181

2009

Rigsby P, Ison C, Brierley M, Ballard R, Hagedorn HJ, Lewis D, Notermans D, Riis J, Robertson P, Seppälä IJT, Rijpkema S. Evaluation of two Human plasma pools as candidate International Standard Preparations for syphilitic antibodies. Biologicals 37: 245-251

Pulickal AS, Gautam S, Clutterbuck EA, Thorson S, Basynat B, Adhikari N, Makepeace K, Rijpkema S, Borrow R, Farrar JJ, Pollard AJ. Kinetics of the natural, humoral immune response to *Salmonella typhi* in Kathmandu, Nepal. Clin Vaccine Immunol 16(10):1413-9.

2008

Barson HV, Mollenkopf H, Kaufmann SHE, Rijpkema S. *In vitro* exposure to anthrax lethal toxin suppresses chemokine production in the human neutrophil-like cell line NB-4. Biochem Biophys Res Comm 374: 288–293.

2007

Duc LH, Hong HA, Atkins HS, Flick-Smith HC, Durrani Z, Rijpkema S, Titball RW, SM Cutting.

Immunisation against anthrax using *Bacillus subtilis* spores expressing the anthrax protective antigen. Vaccine 25(2): 346-55.
Ribeiro S, Rijpkema S, Durrani Z, Florence AT. PLGA-dendrons improve immunogenicity of a DNA vaccine against anthrax in mice. Int J Pharmaceutics 331(2): 228-32.

Wheeler JX, Whiting G, Rijpkema S. Proteomic analysis of the response of the human neutrophil-like cell line NB-4 after exposure to anthrax lethal toxin. Proteomics Clin. Appl. 1: 1266–1279.

Sesardic D, Rijpkema S, Patel BP. New adjuvants: EU Regulatory developments. Expert Rev Vaccines 6 (5): 849-861

2006

Yuen CT, Rijpkema S. A fluorescent peptide substrate for measuring the ADP-ribosylation activity of the cholera toxin A-subunit. Human Vaccines 2:195-199.

2005

Rijpkema SG, Adams T, Rigsby P, Xing DK, Corbel MJ. Investigation in a model system of the effects of combinations of anthrax and pertussis vaccines administered to service personnel in the 1991Gulf War. Human Vaccines 1:165-169.

Adams T, Osborn S, Rijpkema S. An immuno-diffusion assay to assess the protective antigen content of anthrax vaccine. Vaccine 23: 4517-4520.

2004

Rijpkema S, Durrani Z, Lemercinier X, Jones C. Detection of *O*-acetylated Vi polysaccharide of *Salmonella enterica* subspecies *typhi* by enzyme immuno assay. Biologicals 32:11-16

de Jonge R, Durrani Z, Rijpkema SG, Kuipers EJ, van Vliet AHM, Kusters JG. Role of the *Helicobacter pylori* outer membrane proteins AlpA and AlpB in gastric colonisation. J Med Microbiol 53:375-379

Whiting G, Rijpkema S, Adams T, Corbel M. Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine 22: 4245-4251.

Rijpkema SGT, Durrani Z, Ramamurthy T, Nair GB. Various mutations inactivate *wbeT* in *Vibrio cholerae* Inaba isolates. J Med Microbiol 53:1105-1107

Rigsby P, Rijpkema S, Guy EC, Francis J, Gaines Das R. Evaluation of a candidate international standard preparation for human anti-Toxoplasma IgG. J Clin Microbiology 42: 5133-5138